These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38420013)

  • 1. A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Fang S; Xia W; Zhang H; Ni C; Wu J; Mo Q; Jiang M; Guan D; Yuan H; Chen W
    Front Oncol; 2024; 14():1323226. PubMed ID: 38420013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
    Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
    BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.
    Fang Y; Zhang Q; Wu Y; Wu J
    Medicine (Baltimore); 2024 Feb; 103(6):e37170. PubMed ID: 38335419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
    Zhu Q; Tannenbaum S; Kurtzman SH; DeFusco P; Ricci A; Vavadi H; Zhou F; Xu C; Merkulov A; Hegde P; Kane M; Wang L; Sabbath K
    Breast Cancer Res; 2018 Jun; 20(1):56. PubMed ID: 29898762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study.
    Liu Y; Wang Y; Wang Y; Xie Y; Cui Y; Feng S; Yao M; Qiu B; Shen W; Chen D; Du G; Chen X; Liu Z; Li Z; Yang X; Liang C; Wu L
    EClinicalMedicine; 2022 Oct; 52():101562. PubMed ID: 35928032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of Nomograms for Predicting Pathological Complete Response and Tumor Shrinkage Size in Breast Cancer.
    Yan S; Wang W; Zhu B; Pan X; Wu X; Tao W
    Cancer Manag Res; 2020; 12():8313-8323. PubMed ID: 32982426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram.
    Cui H; Zhao D; Han P; Zhang X; Fan W; Zuo X; Wang P; Hu N; Kong H; Peng F; Wang Y; Tian J; Zhang L
    Front Oncol; 2021; 11():718531. PubMed ID: 34888231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy.
    Wang W; Wang X; Liu J; Zhu Q; Wang X; Wang P
    Chin Med J (Engl); 2021 Dec; 135(3):333-340. PubMed ID: 35108228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
    Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.
    Kim JY; Park HS; Kim S; Ryu J; Park S; Kim SI
    Medicine (Baltimore); 2015 Oct; 94(43):e1720. PubMed ID: 26512562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.
    Galvez M; Castaneda CA; Sanchez J; Castillo M; Rebaza LP; Calderon G; Cruz M; Cotrina JM; Abugattas J; Dunstan J; Guerra H; Mejia O; Gomez HL
    World J Clin Oncol; 2018 Apr; 9(2):33-41. PubMed ID: 29651385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution.
    Chen D; Wang Q; Dong M; Chen F; Huang A; Chen C; Lu Y; Zhao W; Wang L
    BMC Cancer; 2023 Oct; 23(1):984. PubMed ID: 37845617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing the Correlation of Rate of Pathological Complete Response and Outcome in Post Neoadjuvant Chemotherapy Setting and Molecular Subtypes of Breast Cancer.
    Omair A; Alkushi A; Alamri G; Almojel T; Alsadun S; Masuadi E; Arabi H; Mohamed AE; Abulkhair OA
    Cureus; 2023 Apr; 15(4):e37449. PubMed ID: 37181967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
    Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
    Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.